1. Home
  2. RFL vs ICCC Comparison

RFL vs ICCC Comparison

Compare RFL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFL
  • ICCC
  • Stock Information
  • Founded
  • RFL 2017
  • ICCC 1982
  • Country
  • RFL United States
  • ICCC United States
  • Employees
  • RFL N/A
  • ICCC N/A
  • Industry
  • RFL Real Estate
  • ICCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RFL Finance
  • ICCC Health Care
  • Exchange
  • RFL Nasdaq
  • ICCC Nasdaq
  • Market Cap
  • RFL 54.4M
  • ICCC 55.5M
  • IPO Year
  • RFL N/A
  • ICCC 1987
  • Fundamental
  • Price
  • RFL $1.34
  • ICCC $6.10
  • Analyst Decision
  • RFL
  • ICCC
  • Analyst Count
  • RFL 0
  • ICCC 0
  • Target Price
  • RFL N/A
  • ICCC N/A
  • AVG Volume (30 Days)
  • RFL 75.0K
  • ICCC 21.7K
  • Earning Date
  • RFL 12-10-2025
  • ICCC 11-13-2025
  • Dividend Yield
  • RFL N/A
  • ICCC N/A
  • EPS Growth
  • RFL N/A
  • ICCC N/A
  • EPS
  • RFL N/A
  • ICCC 0.20
  • Revenue
  • RFL $917,000.00
  • ICCC $28,274,756.00
  • Revenue This Year
  • RFL N/A
  • ICCC N/A
  • Revenue Next Year
  • RFL N/A
  • ICCC N/A
  • P/E Ratio
  • RFL N/A
  • ICCC $30.95
  • Revenue Growth
  • RFL 43.96
  • ICCC 21.75
  • 52 Week Low
  • RFL $1.28
  • ICCC $3.38
  • 52 Week High
  • RFL $3.19
  • ICCC $7.60
  • Technical
  • Relative Strength Index (RSI)
  • RFL 44.34
  • ICCC 43.28
  • Support Level
  • RFL $1.30
  • ICCC $5.90
  • Resistance Level
  • RFL $1.37
  • ICCC $6.28
  • Average True Range (ATR)
  • RFL 0.05
  • ICCC 0.30
  • MACD
  • RFL 0.00
  • ICCC -0.03
  • Stochastic Oscillator
  • RFL 22.50
  • ICCC 13.95

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: